Browse > Article
http://dx.doi.org/10.5483/BMBRep.2022.55.1.075

The therapeutic potential of immune cell-derived exosomes as an alternative to adoptive cell transfer  

Hong, Yeonsun (Biomedical Research Institute, Korea Institute of Science and Technology (KIST))
Kim, In-San (Biomedical Research Institute, Korea Institute of Science and Technology (KIST))
Publication Information
BMB Reports / v.55, no.1, 2022 , pp. 39-47 More about this Journal
Abstract
Adoptive cell transfer (ACT), a form of cell-based immunotherapy that eliminates cancer by restoring and strengthening the body's immune system, has revolutionized cancer treatment. ACT entails intravenous transfer of either tumor-resident or peripheral blood-modified immune cells into cancer patients to mediate anti-tumor response. Although these immune cells control and eradicate cancer via enhanced cytotoxicity against specific tumor antigens, several side effects have been frequently reported in clinical trials. Recently, exosomes, potential cell-free therapeutics, have emerged as an alternative to cell-based immunotherapies, due to their higher stability under same storage condition, lower risk of GvHD and CRS, and higher resistance to immunosuppressive tumor microenvironment. Exosomes, which are nano-sized lipid vesicles, are secreted by living cells, including immune cells. Exosomes contain proteins, lipids, and nucleic acids, and the functional role of each exosome is determined by the specific cargo derived from parental cells. Exosomes derived from cytotoxic effectors including T cells and NK cells exert anti-tumor effects via proteins such as granzyme B and FasL. In this mini-review, we describe the current understanding of the ACT and immune cell-derived exosomes and discuss the limitations of ACT and the opportunities for immune cell-derived exosomes as immune therapies.
Keywords
Adoptive cell transfer; Cancer; Exosome; Immune cell; Immunotherapy;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Kochenderfer JN, Somerville RPT, Lu T et al (2017) Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol 35, 1803-1813   DOI
2 Colombo M, Raposo G and Thery C (2014) Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol 30, 255-289   DOI
3 Raposo G, Nijman HW, Stoorvogel W et al (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183, 1161-1172   DOI
4 Hinshaw DC and Shevde LA (2019) the tumor microenvironment innately modulates cancer progression. Cancer Res 79, 4557-4566   DOI
5 Roma-Rodrigues C, Mendes R, Baptista PV and Fernandes AR (2019) Targeting tumor microenvironment for cancer therapy. Int J Mol Sci 20, 840   DOI
6 Baghban R, Roshangar L, Jahanban-Esfahlan R et al (2020) Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal 18, 59   DOI
7 Yu Y and Cui J (2018) Present and future of cancer immunotherapy: a tumor microenvironmental perspective. Oncol Lett 16, 4105-4113
8 Galluzzi L, Chan TA, Kroemer G, Wolchok JD and Lopez-Soto A (2018) The hallmarks of successful anticancer immunotherapy. Sci Transl Med 10, eaat7807   DOI
9 Chuah S and Chew V (2020) High-dimensional immuneprofiling in cancer: implications for immunotherapy. J Immunother Cancer 8, e000363   DOI
10 Disis ML (2014) Mechanism of action of immunotherapy. Semin Oncol 41 Suppl 5, S3-13   DOI
11 Rosenberg SA and Restifo NP (2015) Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62-68   DOI
12 Fu W, Lei C, Liu S et al (2019) CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. Nat Commun 10, 4355   DOI
13 Yang P, Cao X, Cai H et al (2021) The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth. Cell Immunol 360, 104262   DOI
14 Zhu L, Kalimuthu S, Gangadaran P et al (2017) Exosomes derived from natural killer cells exert therapeutic effect in melanoma. Theranostics 7, 2732-2745   DOI
15 Neviani P, Wise PM, Murtadha M et al (2019) Natural killer-derived exosomal miR-186 inhibits neuroblastoma growth and immune escape mechanisms. Cancer Res 79, 1151-1164   DOI
16 Mathieu M, Martin-Jaular L, Lavieu G and Thery C (2019) Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21, 9-17   DOI
17 Kalluri R and LeBleu VS (2020) The biology, function, and biomedical applications of exosomes. Science 367, eaau6977   DOI
18 Morse MA, Garst J, Osada T et al (2005) A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3, 9   DOI
19 Fais S (2013) NK cell-released exosomes: natural nanobullets against tumors. Oncoimmunology 2, e22337   DOI
20 Hong Y, Kim YK, Kim GB et al (2019) Degradation of tumour stromal hyaluronan by small extracellular vesicle-PH20 stimulates CD103(+) dendritic cells and in combination with PD-L1 blockade boosts anti-tumour immunity. J Extracell Vesicles 8, 1670893   DOI
21 Slattery K and Gardiner CM (2019) NK cell metabolism and TGFbeta - implications for immunotherapy. Front Immunol 10, 2915   DOI
22 Khadka RH, Sakemura R, Kenderian SS and Johnson AJ (2019) Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies. Immunotherapy 11, 851-857   DOI
23 Murthy H, Iqbal M, Chavez JC and Kharfan-Dabaja MA (2019) Cytokine release syndrome: current perspectives. Immunotargets Ther 8, 43-52   DOI
24 Thommen DS and Schumacher TN (2018) T Cell dysfunction in cancer. Cancer Cell 33, 547-562   DOI
25 Hessvik NP and Llorente A (2018) Current knowledge on exosome biogenesis and release. Cell Mol Life Sci 75, 193-208   DOI
26 Escudier B, Dorval T, Chaput N et al (2005) Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med 3, 10   DOI
27 Dai S, Wei D, Wu Z et al (2008) Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 16, 782-790   DOI
28 Riggan L, Shah S and O'Sullivan TE (2021) Arrested development: suppression of NK cell function in the tumor microenvironment. Clin Transl Immunology 10, e1238
29 Melaiu O, Lucarini V, Cifaldi L and Fruci D (2019) Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol 10, 3038   DOI
30 Thery C, Zitvogel L and Amigorena S (2002) Exosomes: composition, biogenesis and function. Nat Rev Immunol 2, 569-579   DOI
31 Zhang X, Liu L, Tang M, Li H, Guo X and Yang X (2020) The effects of umbilical cord-derived macrophage exosomes loaded with cisplatin on the growth and drug resistance of ovarian cancer cells. Drug Dev Ind Pharm 46, 1150-1162   DOI
32 Cheng L, Wang Y and Huang L (2017) Exosomes from M1-polarized macrophages potentiate the cancer vaccine by creating a pro-inflammatory microenvironment in the lymph node. Mol Ther 25, 1665-1675   DOI
33 Wang P, Wang H, Huang Q et al (2019) Exosomes from M1-polarized macrophages enhance paclitaxel antitumor activity by activating macrophages-mediated inflammation. Theranostics 9, 1714-1727   DOI
34 Li J, Li N and Wang J (2020) M1 macrophage-derived exosome-encapsulated cisplatin can enhance its anti-lung cancer effect. Minerva Med [Online ahead of print]
35 Kim MS, Haney MJ, Zhao Y et al (2016) Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells. Nanomedicine 12, 655-664   DOI
36 Tian Y, Li S, Song J et al (2014) A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials 35, 2383-2390   DOI
37 Besse B, Charrier M, Lapierre V et al (2016) Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. Oncoimmunology 5, e1071008   DOI
38 Jong AY, Wu CH, Li J et al (2017) Large-scale isolation and cytotoxicity of extracellular vesicles derived from activated human natural killer cells. J Extracell Vesicles 6, 1294368   DOI
39 Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D and Vujanovic NL (2012) Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 1, 1074-1083   DOI
40 Thery C, Ostrowski M and Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9, 581-593   DOI
41 Skotland T, Sandvig K and Llorente A (2017) Lipids in exosomes: current knowledge and the way forward. Prog Lipid Res 66, 30-41   DOI
42 Nam GH, Choi Y, Kim GB, Kim S, Kim SA and Kim IS (2020) Emerging prospects of exosomes for cancer treatment: from conventional therapy to immunotherapy. Adv Mater 32, e2002440
43 Jankovicova J, Secova P, Michalkova K and Antalikova J (2020) Tetraspanins, more than markers of extracellular vesicles in reproduction. Int J Mol Sci 21, 7568   DOI
44 Zhang Y, Bi J, Huang J, Tang Y, Du S and Li P (2020) Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomedicine 15, 6917-6934   DOI
45 Yang D, Zhang W, Zhang H et al (2020) Progress, opportunity, and perspective on exosome isolation - efforts for efficient exosome-based theranostics. Theranostics 10, 3684-3707   DOI
46 Essand M and Loskog AS (2013) Genetically engineered T cells for the treatment of cancer. J Intern Med 273, 166-181   DOI
47 Tang H, Qiao J and Fu YX (2016) Immunotherapy and tumor microenvironment. Cancer Lett 370, 85-90   DOI
48 Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ and Darcy PK (2016) Reprogramming the tumor microenvironment to enhance adoptive cellular therapy. Semin Immunol 28, 64-72   DOI
49 Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF and Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20, 7-24   DOI
50 Schuster SJ, Svoboda J, Chong EA et al (2017) Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 377, 2545-2554   DOI
51 Rapoport AP, Stadtmauer EA, Aqui N et al (2009) Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin Cancer Res 15, 4499-4507   DOI
52 Kundu S, Gurney M and O'Dwyer M (2021) Generating natural killer cells for adoptive transfer: expanding horizons. Cytotherapy 23, 559-566   DOI
53 Bollino D and Webb TJ (2017) Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy. Transl Res 187, 32-43   DOI
54 Tang X, Yang L, Li Z et al (2018) First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res 8, 1083-1089
55 Magalhaes I, Carvalho-Queiroz C, Hartana CA et al (2019) Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. Expert Opin Biol Ther 19, 811-827   DOI
56 Kochenderfer JN, Dudley ME, Feldman SA et al (2012) B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709-2720   DOI
57 Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM and Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18, 843-851   DOI
58 Shimabukuro-Vornhagen A, Godel P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6, 56   DOI
59 Rohaan MW, Wilgenhof S and Haanen J (2019) Adoptive cellular therapies: the current landscape. Virchows Arch 474, 449-461   DOI
60 Laskowski T and Rezvani K (2020) Adoptive cell therapy: Living drugs against cancer. J Exp Med 217, e20200377   DOI
61 Li L, Jay SM, Wang Y, Wu SW and Xiao Z (2017) IL-12 stimulates CTLs to secrete exosomes capable of activating bystander CD8(+) T cells. Sci Rep 7, 13365   DOI
62 Nikfarjam S, Rezaie J, Kashanchi F and Jafari R (2020) Dexosomes as a cell-free vaccine for cancer immunotherapy. J Exp Clin Cancer Res 39, 258   DOI
63 Ventimiglia LN and Alonso MA (2016) Biogenesis and function of T cell-derived exosomes. Front Cell Dev Biol 4, 84   DOI
64 Ventimiglia LN, Fernandez-Martin L, Martinez-Alonso E et al (2015) Cutting edge: regulation of exosome secretion by the integral MAL protein in T cells. J Immunol 195, 810-814   DOI
65 Mittelbrunn M, Gutierrez-Vazquez C, Villarroya-Beltri C et al (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun 2, 282   DOI
66 Lugini L, Cecchetti S, Huber V et al (2012) Immune surveillance properties of human NK cell-derived exosomes. J Immunol 189, 2833-2842   DOI
67 Dudley ME and Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3, 666-675   DOI
68 Kim GB, Nam GH, Hong Y et al (2020) Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity. Sci Adv 6, eaaz2083   DOI
69 Yang Y, Hong Y, Cho E, Kim GB and Kim IS (2018) Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery. J Extracell Vesicles 7, 1440131   DOI
70 Yang JC and Rosenberg SA (2016) Adoptive T-cell therapy for cancer. Adv Immunol 130, 279-294   DOI
71 Rosenberg SA, Packard BS, Aebersold PM et al (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319, 1676-1680   DOI
72 Robbins PF, Morgan RA, Feldman SA et al (2011) Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 29, 917-924   DOI
73 Feins S, Kong W, Williams EF, Milone MC and Fraietta JA (2019) An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol 94, S3-S9   DOI
74 Bonifant CL, Jackson HJ, Brentjens RJ and Curran KJ (2016) Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics 3, 16011   DOI
75 Zhang Y, Liu Y, Liu H and Tang WH (2019) Exosomes: biogenesis, biologic function and clinical potential. Cell Biosci 9, 19   DOI
76 Koh E, Lee EJ, Nam GH et al (2017) Exosome-SIRPalpha, a CD47 blockade increases cancer cell phagocytosis. Biomaterials 121, 121-129   DOI
77 Shoae-Hassani A, Hamidieh AA, Behfar M, Mohseni R, Mortazavi-Tabatabaei SA and Asgharzadeh S (2017) NK cell-derived exosomes from NK cells previously exposed to neuroblastoma cells augment the antitumor activity of cytokine-activated NK cells. J Immunother 40, 265-276   DOI
78 Di Pace AL, Tumino N, Besi F et al (2020) Characterization of human NK cell-derived exosomes: Role of DNAM1 receptor in exosome-mediated cytotoxicity against tumor. Cancers (Basel) 12, 661   DOI
79 Viaud S, Terme M, Flament C et al (2009) Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One 4, e4942   DOI
80 Neelapu SS, Tummala S, Kebriaei P et al (2018) Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol 15, 47-62   DOI
81 Shimasaki N, Jain A and Campana D (2020) NK cells for cancer immunotherapy. Nat Rev Drug Discov 19, 200-218   DOI
82 Liu S, Galat V, Galat Y, Lee YKA, Wainwright D and Wu J (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol Oncol 14, 7   DOI
83 Klingemann H, Boissel L and Toneguzzo F (2016) Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK Cells. Front Immunol 7, 91   DOI
84 Robbins PF, Kassim SH, Tran TL et al (2015) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res 21, 1019-1027   DOI
85 Tran TH, Mattheolabakis G, Aldawsari H and Amiji M (2015) Exosomes as nanocarriers for immunotherapy of cancer and inflammatory diseases. Clin Immunol 160, 46-58   DOI
86 Morgan RA, Dudley ME, Wunderlich JR et al (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126-129   DOI
87 Johnson LA, Morgan RA, Dudley ME et al (2009) Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546
88 Miliotou AN and Papadopoulou LC (2018) CAR T-cell therapy: a new era in cancer immunotherapy. Curr Pharm Biotechnol 19, 5-18   DOI
89 Comoli P, Chabannon C, Koehl U et al (2019) Development of adaptive immune effector therapies in solid tumors. Ann Oncol 30, 1740-1750   DOI
90 Jeppesen DK, Fenix AM, Franklin JL et al (2019) Reassessment of exosome composition. Cell 177, 428-445 e418   DOI
91 Alexander M, Culos K, Roddy J et al (2021) Chimeric antigen receptor T-cell therapy: a comprehensive review of clinical efficacy, toxicity, and best practices for outpatient administration.Transplant Cell Ther 27, 558-570   DOI
92 Houot R, Schultz LM, Marabelle A and Kohrt H (2015) T-cell-based immunotherapy: adoptive cell transfer and checkpoint inhibition. Cancer Immunol Res 3, 1115-1122   DOI
93 Pitt JM, Andre F, Amigorena S et al (2016) Dendritic cell-derived exosomes for cancer therapy. J Clin Invest 126, 1224-1232   DOI
94 Ott PA, Dotti G, Yee C and Goff SL (2019) An update on adoptive T-cell therapy and neoantigen vaccines. Am Soc Clin Oncol Educ Book 39, e70-e78
95 Parkhurst MR, Yang JC, Langan RC et al (2011) T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther 19, 620-626   DOI
96 Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371, 1507-1517   DOI
97 Hu W, Wang G, Huang D, Sui M and Xu Y (2019) cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front Immunol 10, 1205   DOI
98 Bobrie A, Colombo M, Raposo G and Thery C (2011) Exosome secretion: molecular mechanisms and roles in immune responses. Traffic 12, 1659-1668   DOI
99 Li Q, Wang H, Peng H, Huyan T and Cacalano NA (2019) Exosomes: versatile nano mediators of immune regulation. Cancers (Basel) 11, 1557   DOI
100 Wahlgren J, Karlson Tde L, Glader P, Telemo E and Valadi H (2012) Activated human T cells secrete exosomes that participate in IL-2 mediated immune response signaling. PLoS One 7, e49723   DOI
101 Hong Y, Nam GH, Koh E et al (2018) Exosome as a vehicle for delivery of membrane protein therapeutics, PH20, for enhanced tumor penetration and antitumor efficacy. Adv Funct Mater 28, 1703074   DOI
102 Busatto S, Vilanilam G, Ticer T et al (2018) Tangential flow filtration for highly efficient concentration of extracellular vesicles from large volumes of fluid. Cells 7, 273   DOI
103 Chen YS, Lin EY, Chiou TW and Harn HJ (2020) Exosomes in clinical trial and their production in compliance with good manufacturing practice. Ci Ji Yi Xue Za Zhi 32, 113-120
104 Whitford W and Guterstam P (2019) Exosome manufacturing status. Future Med Chem 11, 1225-1236   DOI